With U.S. drug prices among the highest in the world, generics provide significant financial relief for millions using prescription drugs.
The FDA’s efforts to reduce teen vaping rates will likely result in worse health outcomes by prompting teens to switch to smoking cigarettes.
Epidemics are causes for concern, but before we declare regulation to be the cure, we should question who administers the treatment.
The FDA’s influence in the prescription drug market remains the largest obstacle to deregulation.
Stringent regulations on the e-cigarette market to come.
Right-to-try will never reach its potential without deregulation.
Recent events indicate an urgent need for researchers and policymakers to relearn the basics.
FDA launches anti-vaping campaign.
An example of sweet intentions bearing stale outcomes.
The only reliable remedy to mitigate shortages of any product is to allow competition in the market.